Register for real-time alerts, custom portfolio, and market movers
Period:
Draw Mode:
| Volume | 151,026 |
|
|||||
| News | (2) | ||||||
| Day High | 1.2943 | Low High |
|||||
| Day Low | 1.19 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| IO Biotech Inc | IOBT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| -0.017 | -1.36% | 1.233 | 00:00:11 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 1.24 | 1.19 | 1.2943 | 1.233 | 1.25 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 754 | 151,026 | $ 1.22 | $ 183,518 | - | 0.8163 - 2.215 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 16:00:47 | 46 | $ 1.24 | USD |
IO Biotech Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| 81.03M | 65.88M | - | 0 | -86.08M | -1.31 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | - | - | - |
IO Biotech News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical IOBT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 1.21 | 1.35 | 1.15 | 1.22 | 128,571 | 0.023 | 1.90% |
| 1 Month | 1.54 | 1.79 | 1.15 | 1.34 | 140,602 | -0.307 | -19.94% |
| 3 Months | 1.68 | 1.8453 | 1.15 | 1.47 | 99,165 | -0.447 | -26.61% |
| 6 Months | 1.29 | 2.098 | 1.13 | 1.60 | 124,408 | -0.057 | -4.42% |
| 1 Year | 2.01 | 2.215 | 0.8163 | 1.59 | 153,767 | -0.777 | -38.66% |
| 3 Years | 16.00 | 17.88 | 0.8163 | 3.38 | 99,670 | -14.77 | -92.29% |
| 5 Years | 16.00 | 17.88 | 0.8163 | 3.38 | 99,670 | -14.77 | -92.29% |
IO Biotech Description
| IO Biotech Inc is a clinical-stage biopharmaceutical company developing novel, immune-modulating cancer therapies based on T-win technology platform. The product candidates are designed to induce the immune system to simultaneously target and disrupt multiple pathways that regulate tumor-induced immunosuppression. |
